Alberto Grua Head of Grünenthal Europe and Australia

MILAN, September 22, 2010 - After having handled the worldwide launch of tapentadol, the innovative
drug for the severe acute pain, Alberto Grua has been appointed Grünenthal
Europe and Australia Executive Vice President. Beyond the responsibility of
the Grünenthal subsidiaries Grünin both continents, Grua will be also a
member of the Group Operating Committee of Grünenthal Corporation.

(Photo: www.newscom.com/cgi-bin/prnh/20100922/409552 )

Previously, Grua was Responsible for marketing and sales at
BayerHealthCare, and then Managing Director of the Italian subsidiary of
Grünenthal.

Grua has a business background and graduated in Business Administration
at Bocconi University of Milan.

Grünenthal, a multinational company with head office in Aachen, Germany,
is leader in pain therapy with drugs of great success. Tapentadol -
discovered by Grünenthal and codeveloped with Johnson & Johnson
Pharmaceutical Research & Development, L.L.C, - has been already launched in
U.S., while in Europe it is ongoing marketing.

Maria D'Acquino, +39-02-36557237